Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

Completed · Phase 1

Conditions studied: Smoldering Multiple Myeloma

In brief

The purpose of this study is to determine the safety and tolerability of PVX-410, (a cancer vaccine), treatment regimen for patients with smoldering multiple myeloma as a single agent and in combination with lenalidomide.

Key facts

Study ID
NCT01718899
Run by
OncoPep, Inc.
People needed
22
Starts
2012-11-01
Expected to finish
2016-09-01
Last updated by the study team
2016-09-28

Who can join

Age: 18 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.